Clinical Trial

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

Study acronym: EBIN
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, 2-arm open-label, randomized comparative phase II study. The objective of this trial is to prospectively evaluate whether a sequential approach with an induction period of 12 weeks with encorafenib + binimetinib followed by combination immunotherapy with nivolumab + ipilimumab improves progression free survival compared to combination immunotherapy nivolumab + ipilimumab alone in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2017-07-27; most recent amendment 2025-07-30.
Status change: Recruiting → Active, Not Recruiting 2023-11-02
Status change: Not Yet Recruiting → Recruiting 2018-10-31
Trial Details
NCT Number NCT03235245
Lead Sponsor European Organisation for Research and Treatment of Cancer - EORTC
Conditions Unresectable Stage III Melanoma, Stage IV Melanoma
Enrollment 271 participants
Start Date 2018-10-30
Primary Completion 2023-10-24 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-01